We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In observance of Martin Luther King Jr. Day, Drug Industry Daily will not be published Monday, Jan. 18. The next issue will be published Tuesday, Jan. 19. Read More
The Endocrine Society, a large physicians’ group, is calling on policymakers to include government negotiation as part of an overall strategy to reduce insulin prices. Read More
The Pharmaceutical Care Management Association (PCMA) has filed a lawsuit to halt implementation of President Trump’s drug pricing policy that aims to prevent drugmakers and pharmacy benefit managers from negotiating rebates on prescription medicines. Read More
Eli Lilly CEO David Ricks has expressed concern that the new variant of the coronavirus that causes COVID-19 first reported in South Africa might be resistant to the company’s antibody treatment bamlanivimab. Read More
Brazil’s Butantan Institute reported that Sinovac’s COVID-19 vaccine, CoronaVac, demonstrated an overall efficacy of only 50.38 percent in a phase 3 trial, putting it barely over the World Health Organization’s 50 percent efficacy threshold for approval. Read More
As the Biden administration prepares to take over on Jan. 20, HHS has issued three new regulatory policies that it says will increase transparency and efficiency for the agencies it oversees, including the FDA. Read More
Operation Warp Speed (OWS)’s chief adviser Moncef Slaoui submitted his resignation Tuesday but said he will stay on in that role for 30 days after Jan. 21 to support the incoming administration. Read More
As Johnson & Johnson (J&J) nears the release of critical phase 3 trial results and potential emergency authorization for its promising COVID-19 vaccine, the company has reportedly hit speedbumps in manufacturing doses. Read More